![Ian Thomas](https://profiles-cardiff.imgix.net/attachments/3665?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwyg
Rwy'n Gymrawd Ymchwil yn y grŵp Canser y Gwaed, yng Nghanolfan Gofrestredig UKCRC ar gyfer Ymchwil Treialon ym Mhrifysgol Caerdydd.
Rwyf wedi gweithio ar dreialon clinigol rhyngwladol, yn bennaf mewn lewcemia myeloid aciwt, er 2007, ar ôl gweithio mewn sefydliadau ymchwil diwydiant a chontractau am y 5 mlynedd diwethaf.
Rwyf wedi dechrau datblygu portffolio ymchwil ehangach mewn meysydd o ganlyniadau a adroddwyd gan gleifion, cynwysoldeb mewn treialon clinigol ac mewn meysydd ymchwil haematolegol eraill (o fewn canser a thu hwnt). Fy arbenigedd penodol yw darparu treialon platfform, lle gellir ymchwilio i nifer o gwestiynau ymchwil gwahanol mewn poblogaeth mor eang â phosibl o gleifion.
Drwy'r portffolio treialon clinigol rhyngwladol, rwy'n cydweithio'n eang ledled y DU, Ewrop a'r Unol Daleithiau ac yn gweithio gyda nifer o arianwyr gwahanol gan gynnwys CRUK, BCUK, NIHR a diwydiant.
Cyhoeddiad
2024
- Versluis, J. et al. 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42(34), pp. 4084-4094. (10.1200/JCO.23.02631)
- Russell, N. H. et al. 2024. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology (10.1200/JCO.24.00259)
- Voso, M. T. et al. 2024. Acute promyelocytic leukemia: Long-term outcomes from the HARMONY project. Blood (10.1182/blood.2024026186)
- Rodríguez-Arbolí, E. et al. 2024. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) [Letter to the Editor]. Leukemia 38(10) (10.1038/s41375-024-02378-5)
- Othman, J. et al. 2024. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 144(7), pp. 714-728. (10.1182/blood.2024024310)
- Othman, J. et al. 2024. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19), pp. 1931-1936. (10.1182/blood.2023023096)
- Copland, M. et al. 2024. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 204(3), pp. 871-876. (10.1111/bjh.19220)
2023
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
- Mussai, F. et al. 2023. A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 200(5), pp. 573-578. (10.1111/bjh.18560)
2022
- Loo, S. et al. 2022. Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome [Letter]. Blood 140(22), pp. 2407-2411. (10.1182/blood.2022016567)
- Döhner, K. et al. 2022. Analysis of patient-level data from 3 cooperative group trials confirms a survival advantage for NPM1m patients achieving MRD-negative CR after intensive induction. Blood 140(S1), pp. 6293-6294. (10.1182/blood-2022-159212)
- Freeman, S. D. et al. 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140(S1), pp. 532-533. (10.1182/blood-2022-162245)
- Love, S. B. et al. 2022. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials 23, article number: 757. (10.1186/s13063-022-06680-4)
- Russell, N. H. et al. 2022. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology 198(3), pp. 528-534. (10.1111/bjh.18195)
- Tazi, Y. et al. 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13(1), article number: 4622. (10.1038/s41467-022-32103-8)
- Russell, N. H. et al. 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107(7), pp. 1518-1527. (10.3324/haematol.2021.279010)
- Coats, T. et al. 2022. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology 196(6), pp. 1337-1343. (10.1111/bjh.18013)
- Stimpson, M. L. et al. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196(4), pp. 1113-1117. (10.1111/bjh.17884)
2021
- Dennis, M. et al. 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5(24), pp. 5621-5625. (10.1182/bloodadvances.2021005038)
- Bradbury, C. A. et al. 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385(10), pp. 885-895. (10.1056/NEJMoa2100596)
- Dennis, M. et al. 2021. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. British Journal of Haematology 194(2), pp. 298-308. (10.1111/bjh.17501)
- Burnett, A. K. et al. 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39(8), pp. 890-901. (10.1200/JCO.20.01170)
2020
- Greenwood, R., Pell, J., Foscarini-Craggs, P., Wale, K., Thomas, I. and Bradbury, C. 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21(1), article number: 873. (10.1186/s13063-020-04798-x)
2018
- Burnett, A. K. et al. 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32, pp. 2693-2714. (10.1038/s41375-018-0148-3)
- Freeman, S. D. et al. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36(14), pp. 1486-1497. (10.1200/JCO.2017.76.3425)
2017
- Knapper, S. et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9), pp. 1143-1154. (10.1182/blood-2016-07-730648)
2016
- Burnett, A. et al. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101(6), pp. 724-731. (10.3324/haematol.2016.141937)
2015
- Burnett, A. K. et al. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25), pp. 3878-3885. (10.1182/blood-2015-01-623447)
- Khan, N. et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)
- Dennis, M. et al. 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125(19), pp. 2923-2932. (10.1182/blood-2014-10-608117)
Erthyglau
- Versluis, J. et al. 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42(34), pp. 4084-4094. (10.1200/JCO.23.02631)
- Russell, N. H. et al. 2024. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology (10.1200/JCO.24.00259)
- Voso, M. T. et al. 2024. Acute promyelocytic leukemia: Long-term outcomes from the HARMONY project. Blood (10.1182/blood.2024026186)
- Rodríguez-Arbolí, E. et al. 2024. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) [Letter to the Editor]. Leukemia 38(10) (10.1038/s41375-024-02378-5)
- Othman, J. et al. 2024. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 144(7), pp. 714-728. (10.1182/blood.2024024310)
- Othman, J. et al. 2024. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19), pp. 1931-1936. (10.1182/blood.2023023096)
- Copland, M. et al. 2024. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 204(3), pp. 871-876. (10.1111/bjh.19220)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
- Mussai, F. et al. 2023. A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 200(5), pp. 573-578. (10.1111/bjh.18560)
- Loo, S. et al. 2022. Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome [Letter]. Blood 140(22), pp. 2407-2411. (10.1182/blood.2022016567)
- Döhner, K. et al. 2022. Analysis of patient-level data from 3 cooperative group trials confirms a survival advantage for NPM1m patients achieving MRD-negative CR after intensive induction. Blood 140(S1), pp. 6293-6294. (10.1182/blood-2022-159212)
- Freeman, S. D. et al. 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140(S1), pp. 532-533. (10.1182/blood-2022-162245)
- Love, S. B. et al. 2022. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials 23, article number: 757. (10.1186/s13063-022-06680-4)
- Russell, N. H. et al. 2022. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology 198(3), pp. 528-534. (10.1111/bjh.18195)
- Tazi, Y. et al. 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13(1), article number: 4622. (10.1038/s41467-022-32103-8)
- Russell, N. H. et al. 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107(7), pp. 1518-1527. (10.3324/haematol.2021.279010)
- Coats, T. et al. 2022. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology 196(6), pp. 1337-1343. (10.1111/bjh.18013)
- Stimpson, M. L. et al. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196(4), pp. 1113-1117. (10.1111/bjh.17884)
- Dennis, M. et al. 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5(24), pp. 5621-5625. (10.1182/bloodadvances.2021005038)
- Bradbury, C. A. et al. 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385(10), pp. 885-895. (10.1056/NEJMoa2100596)
- Dennis, M. et al. 2021. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. British Journal of Haematology 194(2), pp. 298-308. (10.1111/bjh.17501)
- Burnett, A. K. et al. 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39(8), pp. 890-901. (10.1200/JCO.20.01170)
- Greenwood, R., Pell, J., Foscarini-Craggs, P., Wale, K., Thomas, I. and Bradbury, C. 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21(1), article number: 873. (10.1186/s13063-020-04798-x)
- Burnett, A. K. et al. 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32, pp. 2693-2714. (10.1038/s41375-018-0148-3)
- Freeman, S. D. et al. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36(14), pp. 1486-1497. (10.1200/JCO.2017.76.3425)
- Knapper, S. et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9), pp. 1143-1154. (10.1182/blood-2016-07-730648)
- Burnett, A. et al. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101(6), pp. 724-731. (10.3324/haematol.2016.141937)
- Burnett, A. K. et al. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25), pp. 3878-3885. (10.1182/blood-2015-01-623447)
- Khan, N. et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)
- Dennis, M. et al. 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125(19), pp. 2923-2932. (10.1182/blood-2014-10-608117)